Alto Neuroscience Inc ANRO
📋 Company Profile
| Industry | Pharmaceuticals |
| Country | US |
| Exchange | NEW YORK STOCK EXCHANGE, INC. |
| Currency | USD |
| IPO Date | 2024-02-02 |
| Shares Out. | 38,830,000 |
| Website | altoneuroscience.com/ ↗ |
| Phone | 17732555012 |
| Employees | 68 |
| Net Income | -$26.2M |
| Free Cash Flow | -$62.9M |
| Total Assets | $276.3M |
| Total Liabilities | $32.9M |
| Equity | $243.4M |
About Alto Neuroscience Inc
Alto Neuroscience Inc is a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging individual's neurobiology to develop personalized and effective treatment options. The company currently consists of different clinical-stage assets such as ALTO-100, ALTO-202, ALTO-207, ALTO-101, and ALTO-300 among others initially targeting depressive disorders and schizophrenia populations as identified by independent brain-based biomarkers.
Alto Neuroscience Inc is a publicly traded company under the ticker symbol ANRO on the NEW YORK STOCK EXCHANGE, INC., operating in the Pharmaceuticals industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
18 analysts (2026-07-01)